

Frank J Beurskens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5824929/publications.pdf>

Version: 2024-02-01

26
papers

2,061
citations

394421

19
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

2247
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. <i>Science</i> , 2014, 343, 1260-1263.	12.6	602
2	Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX. <i>Journal of Immunology</i> , 2009, 183, 749-758.	0.8	230
3	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. <i>PLoS Biology</i> , 2016, 14, e1002344.	5.6	154
4	Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen. <i>Molecular Cell</i> , 2016, 63, 135-145.	9.7	139
5	Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. <i>Science</i> , 2018, 359, 794-797.	12.6	127
6	Complement in therapy and disease. <i>Molecular Immunology</i> , 2015, 67, 117-130.	2.2	124
7	Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. <i>Journal of Immunology</i> , 2012, 188, 3532-3541.	0.8	109
8	Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. <i>Nano Letters</i> , 2019, 19, 4787-4796.	9.1	79
9	Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. <i>PLoS Biology</i> , 2019, 17, e3000323.	5.6	59
10	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. <i>Journal of Immunology</i> , 2016, 197, 1762-1775.	0.8	50
11	DuoHexaBody-CD37 ^Å , a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. <i>Blood Cancer Journal</i> , 2020, 10, 30.	6.2	43
12	Complement in Antibody-Based Tumor Therapy. <i>Critical Reviews in Immunology</i> , 2014, 34, 199-214.	0.5	38
13	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. <i>Haematologica</i> , 2019, 104, 1841-1852.	3.5	38
14	Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. <i>ACS Nano</i> , 2020, 14, 2739-2750.	14.6	36
15	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2126-2138.	4.1	32
16	C1q binding to surface-bound IgG is stabilized by C1r ₂ s ₂ proteases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	32
17	Penetration of antibody ^Å opsonized cells by the membrane attack complex of complement promotes Ca ²⁺ influx and induces streamers. <i>European Journal of Immunology</i> , 2011, 41, 2436-2446.	2.9	31
18	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. <i>Journal of Immunology</i> , 2016, 197, 4829-4837.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. <i>Molecular Immunology</i> , 2016, 70, 13-23.	2.2	26
20	Immune Effector Functions of Human IgG2 Antibodies against EGFR. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 75-88.	4.1	22
21	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. <i>Journal of Immunology</i> , 2017, 198, 1585-1594.	0.8	20
22	A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. <i>Journal of Immunology</i> , 2015, 195, 5077-5087.	0.8	13
23	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. <i>Clinical Immunology</i> , 2017, 181, 24-28.	3.2	11
24	Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. <i>Blood</i> , 2008, 112, 4354-4355.	1.4	6
25	Biophysical Characterization and Stability of Modified IgG1 Antibodies with Different Hexamerization Propensities. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1587-1598.	3.3	5
26	Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". <i>Journal of Immunology</i> , 2018, 200, 2517-2517.	0.8	0